NASDAQ:DWTX Dogwood Therapeutics (DWTX) Stock Price, News & Analysis $1.85 -0.09 (-4.64%) Closing price 04:00 PM EasternExtended Trading$1.82 -0.03 (-1.57%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Dogwood Therapeutics Stock (NASDAQ:DWTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dogwood Therapeutics alerts:Sign Up Key Stats Today's Range$1.77▼$2.0250-Day Range$1.37▼$2.6852-Week Range$1.28▼$9.50Volume120,825 shsAverage Volume77,494 shsMarket Capitalization$62.88 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingHold Company Overview Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential. Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients. Its preclinical pipeline includes antibody and protein candidates targeting key inflammatory and fibrotic pathways. In addition to cardiovascular indications, the company is evaluating opportunities in liver and renal fibrosis, with plans to advance multiple programs into IND‐enabling studies over the coming year. Founded in 2021 and headquartered in Vancouver, British Columbia, Dogwood Therapeutics also maintains research operations in Boston, Massachusetts. The company works in collaboration with academic institutions and clinical research organizations across North America to support its development efforts. Led by an experienced management team with backgrounds in biologics discovery and cardiovascular drug development, Dogwood is positioning itself to address significant unmet needs in fibrotic disease.AI Generated. May Contain Errors. Read More Dogwood Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreDWTX MarketRank™: Dogwood Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 609th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingDogwood Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialDogwood Therapeutics has a consensus price target of $12.00, representing about 548.6% upside from its current price of $1.85.Amount of Analyst CoverageDogwood Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Dogwood Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Dogwood Therapeutics are expected to grow in the coming year, from ($0.67) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dogwood Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dogwood Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDogwood Therapeutics has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Dogwood Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.26% of the float of Dogwood Therapeutics has been sold short.Short Interest Ratio / Days to CoverDogwood Therapeutics has a short interest ratio ("days to cover") of 1.02, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dogwood Therapeutics has recently increased by 78.95%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDogwood Therapeutics does not currently pay a dividend.Dividend GrowthDogwood Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.29 News SentimentDogwood Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Dogwood Therapeutics this week, compared to 3 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dogwood Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.30% of the stock of Dogwood Therapeutics is held by insiders.Percentage Held by Institutions9.05% of the stock of Dogwood Therapeutics is held by institutions.Read more about Dogwood Therapeutics' insider trading history. Receive DWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dogwood Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DWTX Stock News HeadlinesDogwood Completes Enrollment In Halneuron Phase 2b CINP Trial; Topline Data Due November1 hour ago | rttnews.comDogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b TrialSeptember 14 at 8:45 AM | globenewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 14 at 1:00 AM | Stansberry Research (Ad)Biotech Movers: Modular Medical Jumps, InnovAge Revenue Up 16%, Pyxis Data On Deck, Dogwood In FocusSeptember 8, 2026 | rttnews.comDogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain TranscriptSeptember 2, 2026 | seekingalpha.comDogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026August 17, 2026 | globenewswire.comDogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Second Quarter 2026 Financial ResultsAugust 13, 2026 | finanznachrichten.deDogwood Therapeutics Announces Second Quarter 2026 Financial ResultsAugust 13, 2026 | globenewswire.comSee More Headlines DWTX Stock Analysis - Frequently Asked Questions How have DWTX shares performed this year? Dogwood Therapeutics' stock was trading at $4.16 at the beginning of 2026. Since then, DWTX stock has decreased by 55.5% and is now trading at $1.85. How were Dogwood Therapeutics' earnings last quarter? Dogwood Therapeutics, Inc (NASDAQ:DWTX) released its quarterly earnings data on Thursday, August, 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.20. When did Dogwood Therapeutics' stock split? Dogwood Therapeutics shares reverse split on Wednesday, October 9th 2024.A 1-25 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Dogwood Therapeutics IPO? Dogwood Therapeutics (DWTX) raised $30 million in an initial public offering on Thursday, December 17th 2020. The company issued 3,000,000 shares at $9.00-$11.00 per share. How do I buy shares of Dogwood Therapeutics? Shares of DWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today9/14/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (8m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 DWTX's financial health is in the Yellow zone, according to TradeSmith. DWTX has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:DWTX CIK1818844 Webwww.dwtx.com Phone(866) 620-8655FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Price Target for Dogwood Therapeutics$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+548.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($8.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.26 million Net MarginsN/A Pretax MarginN/A Return on Equity-75.55% Return on Assets-40.28% Debt Debt-to-Equity RatioN/A Current Ratio3.89 Quick Ratio3.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.33 per share Price / Book0.79Miscellaneous Outstanding Shares33,990,000Free Float33,891,000Market Cap$62.88 million OptionableN/A Beta1.81 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:DWTX) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhat is Elon Building in Texas?Elon Musk's latest Texas project is massive - three times the size of Central Park and backed by a reported 12...InvestorPlace | SponsoredHow to Align Your Retirement Plan With Trump’s VisionPresident Trump says America is building wealth again, and the U.S. Treasury calls the economy under his admin...American Hartford Gold | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dogwood Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Dogwood Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
